DPP-4 Inhibitors as a New Option for the Management of Type 2 Diabetes.

Lee,  Sang Ah

doi:2013.14.3.128

J Korean Diabetes > Volume 14(3); 2013 > Article

Focused Issue

The Journal of Korean Diabetes 2013;14(3):128-132.
DOI: https://doi.org/10.4093/jkd.2013.14.3.128 Published online September 30, 2013.

DPP-4 억제제의 임상효과

이상아

DPP-4 Inhibitors as a New Option for the Management of Type 2 Diabetes.

Sang Ah Lee

Department of Internal Medicine, Jeju National University School of Medicine, Jeju, Korea. merongfox@gmail.com

Abstract

Dipeptidylpeptidase-4 (DPP-4) inhibitors are new glucose-lowering agents with mechanisms that differ from those of previous oral hypoglycemic agents (OHAs). DPP-4 inhibitors have shown a continuous glucose lowering effect (> 0.5%) when used in monotherapy as well as when used in combination with metformin, sulfonylurea, thiazolidinedione (TZD), insulin, and any other drug. In addition to improving glucose control, DPP-4 inhibitors have also shown a neutral effect on weight gain, improved beta-cell function, and lowered the risk of hypoglycemia. Because of these advantages, DPP-4 inhibitors are widely used in the treatment of all patients with type 2 diabetes mellitus, but especially elderly patients. Therefore, more information regarding these strengths of DPP-4 inhibitors will lead to better treatment of patients with T2DM.

Key Words: Dipeptidylpeptidase-4 inhibitors, Type 2 diabetes mellitus, Efficacy, Safety